Author Archives: wesley

Guangdong Drug Exchange Center Opens Linkage Price Confirmation Window for Listed Drugs – Batch 20260917 Targets Above‑Benchmark VBP Winners and “Four‑Same” Products, With Delisting and Disqualification Risks for Non‑Compliance

Leave a reply

Guangzhou, China – 17 Sep 2026 – The Guangdong Drug Exchange Center launched the viewing and confirmation of linkage price information for some listed drugs (Batch 20260917), covering provincial centralized procurement (VBP) winning products priced above other provinces’ winning prices, same‑enterprise products under price‑differential rules, and “Four‑Same” drugs (same generic name, brand, dosage form and specification) listed above the national lowest listing price — with a confirmation window closing at 17:00 on 20 September 2026 and automatic linkage price adjustment, disqualification or delisting for non‑responsive enterprises.

Notice Snapshot

ItemDetail
AuthorityGuangdong Drug Exchange Center (Guangdong Province, China)
ActionLinkage price viewing & confirmation for selected listed drugs
Batch20260917
Product Scope① VBP winners (incl. limited‑volume winners) whose provincial winning price exceeds other provinces’; ② same‑enterprise winners under price‑differential/comparison rules; ③ “Four‑Same” drugs listed above the national lowest listing price (as of 16 Sep 2026; details in system)
Confirmation WindowImmediate – 20 Sep 2026, 17:00
PlatformGuangdong Drug & Medical Consumables Procurement Subsystem (CA certificate login)
Policy BasisNational drug price governance requirements

Confirmation Paths & Consequences

  • Viewing Path (VBP winners above other provinces’ prices): Log in with CA certificate → “Drug Centralized Procurement Management – Drug Price Management – Drug Price Publication – Provincial VBP Winning Product Linkage Price Information Viewing (Batch 20260917).”
  • Confirmation Path (price‑differential winners & “Four‑Same” drugs): Log in with CA certificate → “Drug Price Confirmation – Provincial VBP Winning Products and ‘Four‑Same’ Drug Linkage Price Confirmation (Batch 20260917).”
  • Appeal Mechanism: Enterprises disputing prices must upload appeal materials stamped with the company seal on every page via the designated appeal attachment path within the window; late objections or missing evidence will in principle not be accepted.
  • VBP Winners Above Other Provinces: No objection, or appeal rejected → winning price adjusted downward via linkage automatically.
  • Price‑Differential Winners: Confirm within deadline → linkage adjustment applies; refuse confirmation with appeal rejected, or miss the deadline → winning qualification cancelled per procurement documents.
  • “Four‑Same” Listed Drugs: Confirm within deadline → unified price adjustment across the province’s three platforms; refuse with appeal rejected, or miss the deadline → listing revoked, with relisting only via a fresh application through the standard listing process.
  • Ongoing Self‑Check Duty: Enterprises must monitor prices in other provinces and submit price adjustment applications through the subsystem within 30 days of any new lower winning or listing price taking effect elsewhere.

Sector Background

  • Linkage Price Mechanism: Cross‑province price linkage forces listed and VBP‑winning prices toward the national lowest benchmark, a core pillar of China’s drug price governance that compresses inter‑provincial price gaps.
  • “Four‑Same” Targeting: Identical generic name, brand, dosage form and specification — the tightest comparability standard, closing arbitrage where the same product holds different prices across platforms.
  • Three‑Platform Unification: Confirmed “Four‑Same” adjustments apply uniformly across Guangdong’s three procurement platforms, eliminating within‑province price fragmentation.
  • Contact Channels: Online customer service via the Guangdong Drug Exchange Center website; hotlines 020‑87709875 / 020‑38036197 (weekdays 8:30–12:00, 14:00–17:30).

Market Impact & Outlook

  • Immediate Revenue Risk: For affected products, linkage adjustment means direct price cuts in Guangdong, one of China’s largest pharmaceutical markets — material for enterprises with concentrated provincial exposure.
  • Compliance Deadline Pressure: The four‑day window (closing 20 Sep, 17:00) makes timely CA‑certificate login and price confirmation operationally critical; missed deadlines trigger disqualification or delisting without further recourse.
  • National Price Discipline: The 30‑day self‑reporting duty institutionalizes continuous downward price surveillance — enterprises should embed cross‑province price monitoring into routine market‑access operations.
  • Strategic Considerations: Companies facing steep linkage cuts must weigh confirmation against withdrawal economics per product, factoring in relisting costs and the risk of setting new national price precedents.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding linkage price adjustments, appeals outcomes and potential disqualification or delisting of listed drugs in Guangdong. Actual price changes depend on enterprise confirmations, appeal adjudications and system data as of the batch cut‑off date, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100576933975691264

Guangdong Drug Exchange Center Publishes First Batch of Newly Listed Medical Consumables for September 2026 – Batch GDHCTYGW34‑20260901 Enters Unified Listing Catalogue, Enabling Hospital Contract Transactions

Leave a reply

Guangzhou, China – 16 Sep 2026 – The Guangdong Drug Exchange Center published the first batch of September 2026 newly listed medical consumables (batch code GDHCTYGW34‑20260901), incorporating the approved products into the province’s Unified Medical Consumables Listing Catalogue effective immediately, and reminding manufacturers and distributors to complete delivery relationship maintenance in the Guangdong procurement subsystem so that medical institutions may initiate contract transactions.

Listing Snapshot

ItemDetail
AuthorityGuangdong Drug Exchange Center (Guangdong Province, China)
ActionPublication of newly listed (挂网) medical consumable products
BatchSeptember 2026, First Batch – GDHCTYGW34‑20260901
Publication Date16 September 2026
Product CountNot disclosed in the notice; full product information table attached to the official notice
StatusProducts unified into the “Unified Medical Consumables Listing Catalogue” effective immediately
Policy BasisAnnouncements on unifying the province‑wide newly added consumables listing process and on optimizing consumables listing management

Listing Details & Platform Access

  • Result Access: Applicant enterprises can log in to the Guangdong Drug and Medical Consumables Procurement Subsystem using a CA certificate and view outcomes via “Consumables Centralized Procurement Management – Consumables Listing Application – Published Results.”
  • Transaction Precondition: Medical institutions may initiate contract transactions only after the listed product’s delivery relationship meets requirements — the gating step between listing publication and actual hospital purchasing.
  • Action Required: Declaring enterprises are urged to complete delivery relationship maintenance in the procurement subsystem as soon as possible to avoid transaction delays; the operation guide is downloadable from the platform’s “Member Services – Procedural Guide” section.
  • Product Scope: Specific products, categories and quantities were not disclosed in the notice text; they are enumerated in the attached batch product information table.

Sector Background

  • Listing (挂网) Mechanism: In China’s provincial procurement architecture, “listing” registers a consumable product on the official exchange platform with declared pricing, enabling public hospitals to transact through the centralized system — a prerequisite for hospital market access in the province.
  • Guangdong’s Scale: As one of China’s largest provincial medical consumables markets, Guangdong’s exchange platform processes high‑volume listing batches on a rolling schedule, with the batch numbering (GDHCTYGW34‑20260901) reflecting a systematic, periodic publication cadence.
  • Process Unification: The referenced announcements standardized the province‑wide newly added listing process and optimized listing management — part of a broader national push toward consistent, transparent consumables procurement administration across provinces.

Market Impact & Outlook

  • Market Access Milestone: Enterprises with products in this batch gain immediate eligibility for hospital transactions across Guangdong once delivery relationships are validated — converting regulatory listing into commercial opportunity.
  • Compliance Urgency: The gap between listing publication and transactability hinges on delivery relationship maintenance; manufacturers slow to complete this step risk losing early sales windows to competitors already transacting.
  • Pricing Transparency: Listing places products in the unified catalogue with declared prices visible within the platform, reinforcing price benchmarking pressure across the provincial consumables market.
  • Forward Pipeline: Subsequent monthly batches will follow the same rolling cadence — suppliers not included in this batch should track upcoming September and October publications and ensure CA certificate credentials and delivery networks are pre‑positioned.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the listing, transaction readiness and commercial uptake of medical consumables published in Guangdong’s September 2026 first batch. Actual transaction volumes, delivery relationship approvals and market performance depend on platform processes, enterprise compliance and hospital procurement decisions, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100141153948012544

Ningxia MPA Launches “Spring Rain Action” (2026–2028) to Convert Clinical Innovation into Marketed Medical Devices – Three‑Year, Five‑Phase Program Builds Doctor‑Engineer Translation Ecosystem in Northwest China

Leave a reply

Yinchuan, China – 16 Sep 2026 – The Ningxia Hui Autonomous Region Medical Products Administration (Ningxia MPA) issued the Implementation Plan for the “Spring Rain Action” (2026–2028) to Transform Clinical Innovation Achievements of Medical Devices (Ningyao Jianfa [2026] No. 44), a three‑year program that solicits clinician‑originated device innovations and channels them through screening, matchmaking, cultivation and registration support — with joint execution by the region’s industry & IT, health and market regulation departments — aiming to bring a batch of med‑engineering integrated landmark products to market.

Policy Snapshot

ItemDetail
AuthorityNingxia Hui Autonomous Region MPA (lead), with Department of Industry & Information Technology, Health Commission, Market Regulation Department
Document“Spring Rain Action” (2026–2028) Implementation Plan – Ningyao Jianfa [2026] No. 44
ObjectiveConvert clinical innovation achievements into registered medical devices; build an ecosystem of “clinical idea supply – med‑engineering collaborative R&D – central‑local nurturing – cross‑department promotion”
HorizonThree years: 2026–2028
MechanismFull‑chain workflow: collection & screening → matchmaking → coaching & cultivation → commercialization
Original Documentnxyjj.nx.gov.cn (published 16 September 2026)

Program Architecture – Five Phases

  • Organizational Preparation (Sept 2026): Joint issuance of the plan; four departments each appoint a liaison to coordinate daily work.
  • Policy Promotion (Sept–Oct 2026): Online publicity plus offline consultation targeting medical institutions at all levels; on‑site policy briefings in device industrial parks; a dedicated “Spring Rain Action” column on the MPA website to publicize screening progress.
  • Collection & Screening (Nov 2026 – Nov 2027): Medical institutions submit convertible clinical innovations via the official Project Information Collection Form; the Ningxia MPA drafts Clinical Value Screening Evaluation Criteria for joint departmental approval, screens projects, and publicizes selected entries (with applicant consent).
  • Matchmaking (Dec 2027 – Jun 2028): Multi‑department project matchmaking sessions connect hospitals, research institutes and interested companies/investors; enterprises file an Intent Matching Form, and converted products are reported via a Converted Product List.
  • Product Cultivation (Jun 2028 – Dec 2028, continuing per R&D cycles): Projects entering development are designated key cultivation products under an “active outreach, one‑product‑one‑policy, full‑course tracking, dedicated team support” regime — with Class I/II devices guided through R&D, registration and filing, and Class III candidates (especially innovative/priority‑review products) recommended to the NMPA Center for Medical Device Evaluation for pre‑review services and to national “open competition for best candidates” and key R&D programs.

Roles & Responsibilities

  • Ningxia MPA (lead): Sets screening criteria; provides pre‑review consultation, standards research, product design optimization, testing, clinical trial guidance and R&D‑review linkage services; reports progress regularly to the NMPA.
  • Industry & IT Department: Mobilizes regional industrial resources; drives precise hospital‑enterprise matchmaking; supports capacity and market expansion.
  • Health Commission: Encourages medical institutions to open clinical trial resources and submit qualifying innovation projects; supports registration studies.
  • Market Regulation Department: Provides patent guidance — conversion, layout and infringement disputes — including a patent pre‑examination fast track for projects in new materials and high‑end equipment manufacturing.
  • Hospitals & Clinicians: Ensure research compliance, ethics review and subject protection; submit and drive clinical innovation projects; institutionalize成果转化 mechanisms.
  • Device Companies & Investors: Negotiate investment or IP transfer agreements; jointly complete product finalization, clinical trials, registration and compliant production.

Market Impact & Outlook

  • Translation Gap Addressed: The program directly targets the “valley of death” between clinician ideas and registered products — pairing clinical demand with engineering and regulatory coaching rarely available to individual practitioners.
  • Regional Innovation Signal: For a western region with a smaller medtech base, dedicated provincial‑level translation machinery plus links to NMPA pre‑review channels is a meaningful incentive for device developers and hospital innovators in Ningxia.
  • Regulatory Fast‑Track Access: Projects preliminarily identified as Class III innovative or priority‑review candidates may reach national‑level review support — the most consequential carrot in the plan for high‑value products.
  • Monitoring Cadence: Departments file biannual progress reports (by 15 May and 15 Nov annually) to the Ningxia MPA, which consolidates and reports to the NMPA by end of May and November — creating a built‑in disclosure rhythm for tracking program results through 2028.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of Ningxia’s “Spring Rain Action” program, including project screening outcomes, product development timelines and potential registration milestones. Actual results depend on project quality, departmental coordination, regulatory reviews and market conditions, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: http://nxyjj.nx.gov.cn/zwgk/gkml/zcwj11/gzwj_37845/zcfgc/202609/t20260916_5344613.html